Skip to main content


Read the article. Take the short quiz.And receive your free samples.


As of January 1, 2017, the ADA CDT code D4346 went into effect for patients classified with generalized moderate to severe gingival inflammation. Since gingivitis is prevalent at all ages,1 this is big news.

The opportunity this presents for your patients. AND your practice.

The introduction of CDT code D4346 is a game-changer, filling a huge gap that existed in procedure coding. Up until now, you have only had treatment code D1110 for patients who have healthy gums or mild inflammation. There was also treatment code D4341-D4342 for patients who have periodontitis with bone and attachment loss. Now, you have the appropriate code to document how you have treated patients with generalized moderate to severe inflammation.2,3

With this new code, you can bring the importance of gingival inflammation to the forefront for practitioners as well as patients. It enables you to follow an appropriate and defined treatment plan for gingivitis, which could ultimately help you in preventing periodontitis.

Understanding the New CDT Guidelines for Treatment

By refining treatment with an appropriate code that recognizes the differences between preventive care and therapeutic care, CDT 4346 helps you elevate the standard of oral care by enabling patients with moderate to severe gingivitis to be healthier. Because this code is not age-based, CDT 4346 can help in earlier intervention and disease prevention in essentially all of your patients.


You know the importance of patients maintaining a proper oral care routine that includes brushing, flossing, and rinsing. Now that you can diagnose and treat gingivitis earlier and more effectively, you can help get your patients back on track to improved oral health sooner by recommending the addition of LISTERINE® Antiseptic mouthrinse to their daily oral care routine to help prevent plaque and gingivitis.

Only Listerine® brand meets the high standards of the ADA58

LISTERINE® Antiseptic is the #1 recommended mouthrinse and the only brand to receive the ADA Seal of Acceptance to prevent and reduce plaque and gingivitis.9

More effective than Crest® Pro-Health™ in reducing gingivitis10

LISTERINE® Antiseptic has been proven to reduce gingivitis by 65% more thanCrest® Pro-Health10‡

Only over-the-counter mouthrinse with efficacy comparable to prescription-strength brands8,10

Even when compared to prescription-only Peridex™, LISTERINE® Antiseptic was the only branded over-the-counter mouthrinse to produce comparable gingivitis reduction results at 6 months. Importantly, LISTERINE® Antiseptic does not contain CPC, which has been associated with tooth staining.

Take the Office Essentials®
Knowledge Challenge

Receive free patient samples of these products by taking our short quiz:

Learn more about the impact the approval of code D4346 can have on your practice.

Explore evidence from a study about LISTERINE® Antiseptic and the reduction of plaque and gingivitis.

See which LISTERINE® products you should consider recommending to your patients.


References: 1. Marcenes W, Kassebaum NJ, Bernabé E, et al. Global burden of oral conditions in 1990-2010: a systematic analysis. J Dent Res. 2013;92(7):592-597. 2. New gingivitis code helps you provide ethical care. Dental Products Report Website. Accessed January 16, 2017. 3. D1110 and D4910. What’s the difference, and why is it hard to explain? RDH Magazine Website. issue-4/features/d110-and-d4910.html. Accessed January 16, 2017. 4. A Guide to Reporting D4346. American Dental Association Website. Accessed January 24, 2017. 5. Sheen S, Owens J, Addy M. The effect of toothpaste on the propensity of chlorhexidine and cetyl pyridinium chloride to produce staining in vitro: a possible predictor of inactivation. J Clin Periodontol. 2001;28(1):46-51. 6. Sheen S, Addy M. An in vitro evaluation of the availability of cetylpyridinium chloride and chlorhexidine in some commercially available mouthrinse products. Br Dent J. 2003;194(4):207-210. 7. Sheen S, Eisenburger M, Addy M. Effect of toothpaste on the plaque inhibitory properties of a cetylpyridinium chloride mouth rinse. J Clin Periodontol. 2003;30(3):255-260. 8. Overholser CD, Meiller TF, DePaola LG, Minah GE, Niehaus C. Comparative effects of 2 chemotherapeutic mouthrinses on the development of supragingival dental plaque and gingivitis. J Clin Periodontol. 1990;17(8):575-579. 9. ADA seal product report. Listerine® antiseptic. American Dental Association Website. ada-seal-of-acceptance/ada-seal-products/product-category/product-report/?product1d=4438&company=Johnson+%26+Johnson+Healthcare+Products&category=Plaque/Gingivitis%20Control%20Mouthrinse. Accessed January 24, 2017. 10. Data on file, Johnson & Johnson Consumer Inc.